Basit öğe kaydını göster

dc.contributor.authorCokugras, Haluk
dc.contributor.authorKasapcopur, Ozgur
dc.contributor.authorArisoy, Nil
dc.contributor.authorKilic, Omer
dc.contributor.authorCamcioglu, Yildiz
dc.contributor.authorAkcakaya, Necla
dc.date.accessioned2021-03-03T08:11:23Z
dc.date.available2021-03-03T08:11:23Z
dc.date.issued2012
dc.identifier.citationKilic O., Kasapcopur O., Camcioglu Y., Cokugras H., Arisoy N., Akcakaya N., "Is it safe to use anti-TNF-alpha agents for tuberculosis in children suffering with chronic rheumatic disease?", RHEUMATOLOGY INTERNATIONAL, cilt.32, sa.9, ss.2675-2679, 2012
dc.identifier.issn0172-8172
dc.identifier.othervv_1032021
dc.identifier.otherav_162c0270-671b-4c7e-ab5b-a57e49af52bc
dc.identifier.urihttp://hdl.handle.net/20.500.12627/20267
dc.identifier.urihttps://doi.org/10.1007/s00296-011-2030-8
dc.description.abstractTo determine the incidence of latent tuberculosis infection and evaluate the follow-up protocol of the patients diagnosed with juvenile idiopathic arthritis (JIA) and other chronic rheumatologic diseases treated with anti-TNF-alpha treatment (etanercept, infliximab, adalimumab) in Turkey, 144 patients were evaluated retrospectively for the development of tuberculosis. Patients were evaluated every 6 months for tuberculosis using history, physical examination, tuberculin skin test (TST), chest radiographs, and, when required, examination of sputum/early morning gastric aspirates for acid-fast bacilli and chest tomography. A tuberculin skin test over 10 mm induration was interpreted as positive. Patients were diagnosed with JIA (n = 132), enthesitis-related arthritis (ERA; n = 14), juvenile psoriatic arthritis (JPsA; n = 4), chronic idiopathic uveitis (n = 4), and chronic arthritis related to FMF (n = 8). Mean age was 12.25 +/- A 3.96 years (4.08-19.41 years), mean duration of illness was 5.86 +/- A 3.77 years (0.66-15 years), and the mean duration of anti-TNF-alpha treatment was 2.41 +/- A 1.47 years (0.6-7 years). Anti-TNF-alpha agents prescribed were etanercept (n = 133), infliximab (n = 30), and adalimumab (n = 6). When unresponsive to one anti-TNF-alpha therapy, patients were switched to another. There was no history of contact with individuals having tuberculosis. During follow-up, seven patients (4.8%) with positive TST were given INH prophylaxis. One oligoarticular JIA patient (0.69%) diagnosed with secondary uveitis who had been followed for 5 years and had been using infliximab for 2 years, developed a positive Quantiferon-TB test while on INH prophylaxis. He was started on an anti-tuberculosis drug regimen. In conclusion, anti-TNF-alpha treatment in children with chronic inflammatory disease is safe. Follow-up every 6 months of children on anti-TNF-alpha treatment with respect to tuberculosis by the pediatric infectious disease department is important to prevent possible complications.
dc.language.isoeng
dc.subjectİç Hastalıkları
dc.subjectİmmünoloji ve Romatoloji
dc.subjectDahili Tıp Bilimleri
dc.subjectSağlık Bilimleri
dc.subjectTıp
dc.subjectKlinik Tıp (MED)
dc.subjectKlinik Tıp
dc.subjectROMATOLOJİ
dc.titleIs it safe to use anti-TNF-alpha agents for tuberculosis in children suffering with chronic rheumatic disease?
dc.typeMakale
dc.relation.journalRHEUMATOLOGY INTERNATIONAL
dc.contributor.departmentİstanbul Üniversitesi , ,
dc.identifier.volume32
dc.identifier.issue9
dc.identifier.startpage2675
dc.identifier.endpage2679
dc.contributor.firstauthorID42377


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster